Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cagrilintide - Novo Nordisk

Next Previous
Drug Profile

Cagrilintide - Novo Nordisk

Alternative Names: AM-833 - Novo Nordisk; AM833; NN 9838; NNC-0174-0833

Latest Information Update: 19 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
  • Mechanism of Action Amylin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis; Obesity

Most Recent Events

  • 12 Jun 2025 Phase-I clinical trials in Obesity in Denmark (SC) (NCT07010432)
  • 30 May 2025 Novo Nordisk plans a phase I trial for Obesity in Denmark in June 2025 (SC) (NCT07010432)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Obesity in China (SC, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top